JP2025523933A5 - - Google Patents

Info

Publication number
JP2025523933A5
JP2025523933A5 JP2025502639A JP2025502639A JP2025523933A5 JP 2025523933 A5 JP2025523933 A5 JP 2025523933A5 JP 2025502639 A JP2025502639 A JP 2025502639A JP 2025502639 A JP2025502639 A JP 2025502639A JP 2025523933 A5 JP2025523933 A5 JP 2025523933A5
Authority
JP
Japan
Prior art keywords
sequence
monoclonal antibody
variable region
chain variable
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025502639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025523933A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2023/108389 external-priority patent/WO2024017331A1/zh
Publication of JP2025523933A publication Critical patent/JP2025523933A/ja
Publication of JP2025523933A5 publication Critical patent/JP2025523933A5/ja
Pending legal-status Critical Current

Links

JP2025502639A 2022-07-20 2023-07-20 抗アドレノメデュリン非中和抗体、その製造方法及び使用 Pending JP2025523933A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202210863441 2022-07-20
CN202210863441.9 2022-07-20
PCT/CN2023/108389 WO2024017331A1 (zh) 2022-07-20 2023-07-20 一种抗肾上腺髓质素非中和抗体、其制备方法及应用

Publications (2)

Publication Number Publication Date
JP2025523933A JP2025523933A (ja) 2025-07-25
JP2025523933A5 true JP2025523933A5 (https=) 2025-08-08

Family

ID=89617212

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2025502639A Pending JP2025523933A (ja) 2022-07-20 2023-07-20 抗アドレノメデュリン非中和抗体、その製造方法及び使用

Country Status (9)

Country Link
US (1) US20260035456A1 (https=)
EP (1) EP4559936A1 (https=)
JP (1) JP2025523933A (https=)
KR (1) KR20250040987A (https=)
CN (1) CN119546634A (https=)
AU (1) AU2023310494A1 (https=)
IL (1) IL318511A (https=)
TW (2) TWI870936B (https=)
WO (1) WO2024017331A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025152915A1 (zh) * 2024-01-16 2025-07-24 上海济煜医药科技有限公司 抗肾上腺髓质素抗体在预防或治疗脑卒中的应用
WO2025248139A1 (en) 2024-05-31 2025-12-04 4TEEN4 Pharmaceuticals GmbH Use of adrenomedullin or fragments thereof in the treatment of a patient in need thereof
WO2026046978A1 (en) * 2024-08-26 2026-03-05 Pam Theragnostics Gmbh Anti-adm antibodies, anti-adm antibody fragment or anti-adm non-ig scaffold for therapy or prevention of immune effector cell therapy side effects

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2780371T (pt) * 2011-11-16 2019-01-30 Adrenomed Ag Anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou uma estrutura não ig anti-adm para a regulação do equilíbrio de fluidos num doente com uma doença aguda ou crónica
IL283215B2 (en) * 2011-11-16 2024-05-01 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same
EP3339324A1 (en) * 2016-12-22 2018-06-27 sphingotec GmbH Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
HRP20241795T1 (hr) * 2017-09-25 2025-03-14 Adrenomed Ag Anti-adrenomedulin (adm) – vezujući entitet za uporabu u terapiji ili prevenciji simptoma bolesti

Similar Documents

Publication Publication Date Title
JP2025523933A5 (https=)
CN104144948B (zh) 用于治疗的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig骨架
US20240368268A1 (en) Method of modulating the activity of adrenomedullin in a subject in need of therapeutic intervention for organ dysfunction or organ failure associated with adrenomedullin (adm) activity by administering an anti-adrenomedullin (adm) antibody or an anti-adm fragment to the subject
US9304127B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment for use in therapy
US9402900B2 (en) Methods of modulating adrenomedullin by administering an anti-adrenomedullin (ADM) antibody
AU2012338730B2 (en) Anti-adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition
JP7145162B2 (ja) 化膿性汗腺炎の処置
JP2025087764A5 (https=)
WO2023250463A2 (en) Combination therapies with an anti-factor xi/factor xia antibody
RU2854796C1 (ru) Связующее вещество против адреномедуллина (adm) для применения в терапии пациентов в состоянии шока
US20230250166A1 (en) Anti-adrenomedullin (adm) binder for use in therapy of patients in shock
CA2856141E (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
HK40069661A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
JP2023520216A5 (https=)
HK40006910A (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or ant-adm non-ig scaffold for use in therapy